U.S. Department of Health, 2005-09-26: The OIG audit Congress required under MMA section 303 found that hematology and oncology practices generally bought cancer drugs for less than ASP+6%, keeping the difference. Practices could buy below the reimbursement rate in most practice-months studied.
could generally purchase drugs for the treatment of cancer patients at less than the MMA-established reimbursement rates.
p. 4 (Results of Review)
U.S. Department of Health, 2005-09-26: The OIG audit Congress required under MMA section 303 found that hematology and oncology practices generally bought cancer drugs for less than ASP+6%, keeping the difference. Practices could buy below the reimbursement rate in most practice-months studied. Federal audit, no funder or conflicts. No maker (39 HCPCS codes, 94% of $4.5B in 2004 Medicare-allowed oncology drug spending). Comparator: acquisition invoice prices vs the 106%-of-ASP payment. This is the primary evidence that ASP+6% is a margin to the administering practice, not a cost pass-through. Study type: regulatory record.
